SiNtx Technologies Inc (SINT)

[boston745]

There is a specific SEC rule against short selling stock just before a public offering and then buying back the stock in the offering

According to the SEC rule referenced, Affiliate businesses (Fund B, C, D, etc) can short the company while Fund A buys the offering. This could be another reason why Anson is but one of many funds in this family of funds.

(3) Investment companies. Paragraph (a) of this section shall not prohibit an investment company (as defined by Section 3 of the Investment Company Act) that is registered under Section 8 of the Investment Company Act, or a series of such company (investment company) from purchasing an offered security where any of the following sold the offered security short during the Rule 105 restricted period:

(i) An affiliated investment company, or any series of such a company; or

https://web.archive.org/web/20200809144313/https://www.law.cornell.edu/cfr/text/17/242.105

Still, my post proves beyond a shadow of all doubt that there has been a conspiracy of funds working to short SINT despite claims no such things were going on by the very accounts which distort facts about Sintx on ST/Ihub.

This posts shows shows that there is a family of funds associated Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174597546

This post shows how this group of funds work together to short offerings and buy them so, as the above shows, to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544

One of the most obvious examples of them trading on material non-public information was the run up of SINT to $2,418 ($12.09 pre-RS) on Feb 3rd 2023. This group seemingly ran the price up ahead of this offering price news to the aforementioned $2,418 and naked shorted just 3 trading days before the offering where the stockprice dropped from close of $1,863 ($9.31) Feb 3rd and closed at 666.52 (3.33) on Feb 8th. Two of Anson family of funds bought this offering. Lind Global and Intercoastal Capital. If either of these two funds naked shorted this offering this would be a violation but its likely that the other funds in this family did the naked shorting. Another interesting thing to note is how each fund took turns buying offerings thus spreading out profits and tax write offs between funds.

This article indicates how Anson and this group of funds utilize european markets for their naked shorting. Do they even need to do this via European markets when they have off-shore funds in the Caribbean?

How Anson Funds Skirts Naked Shorting Rules with Help from Big Banks, Brokers and European Regulators.
https://marketfrauds.to/moez-kassam-anson-funds-the-big-secret/

I suspect this article is truth mixed with lies as very little is sourced to anything verifiable. Not likely entirely how they operate (missing sister funds for instance) and is meant as misdirection. Still it'll contain some nuggets of truth within.

========================================

Not only have i shown there has in fact been a conspiracy of funds shorting SINT since 2015 (they've also have several accounts distorting facts about Sintx on ST/IHUB), ive also shown that Zimmer Biomet/subsidiary is/was Sintx strategic partner pertaining to the testing and development of hip implant utilizing Sintx femoral head. This after being told several times that Zimmer Biomet supplying its liners for this testing means nothing.

Proof Zimmer Biomet is one of Sintx strategic partners:

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017

This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research

These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.

Quote Sources:

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf